Kenvue (NYSE:KVUE) Rating Increased to Buy at Rothschild & Co Redburn

Key Points

• Kenvue (NYSE:KVUE) has been upgraded to a "buy" rating by analysts at Rothschild & Co Redburn, with a target price set at $22.00, indicating a potential 35.79% upside from the previous close.
• The company reported a quarterly earnings per share of $0.29, slightly above the expected $0.28, but revenue of $3.84 billion fell short of the $3.94 billion estimate.
• Approximately 97.64% of Kenvue's stock is owned by institutional investors, which have shown increased activity, with significant stakes acquired recently.

Kenvue (NYSE:KVUE - Get Free Report) was upgraded by analysts at Rothschild & Co Redburn from a "neutral" rating to a "buy" rating in a report released on Friday, Marketbeat Ratings reports. The firm presently has a $22.00 target price on the stock, down from their previous target price of $22.50. Rothschild & Co Redburn's price target would indicate a potential upside of 35.79% from the company's previous close.

Several other equities research analysts have also recently issued reports on KVUE. Barclays cut their target price on Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research note on Tuesday, July 15th. Royal Bank Of Canada cut their target price on Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a research note on Friday, August 8th. UBS Group cut their target price on Kenvue from $25.00 to $23.00 and set a "neutral" rating for the company in a research note on Thursday, July 17th. Evercore ISI dropped their price objective on Kenvue from $23.00 to $18.00 and set an "in-line" rating for the company in a research note on Tuesday. Finally, Zacks Research upgraded Kenvue to a "strong sell" rating in a report on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Kenvue has an average rating of "Hold" and an average price target of $23.21.

Kenvue Price Performance

KVUE stock opened at $16.20 on Friday. The business has a fifty day moving average of $20.48 and a two-hundred day moving average of $21.88. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The stock has a market cap of $31.09 billion, a price-to-earnings ratio of 21.89, a price-to-earnings-growth ratio of 2.42 and a beta of 0.83. Kenvue has a 52-week low of $16.14 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01. The company had revenue of $3.84 billion during the quarter, compared to analysts' expectations of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm's quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, research analysts anticipate that Kenvue will post 1.14 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Pittenger & Anderson Inc. acquired a new position in Kenvue during the 1st quarter worth $30,000. Trust Co. of Vermont grew its stake in Kenvue by 266.8% during the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company's stock worth $33,000 after purchasing an additional 1,150 shares in the last quarter. TruNorth Capital Management LLC acquired a new position in Kenvue during the 1st quarter worth $36,000. Truvestments Capital LLC acquired a new position in Kenvue during the 1st quarter worth $37,000. Finally, Clal Insurance Enterprises Holdings Ltd grew its stake in Kenvue by 378.5% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after purchasing an additional 1,287 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.